MAPT and Alzheimer disease: When tested in several in vitro models of AD, MitoQ’s ability to limit ROS generation, re-establish the optimal mitochondrial membrane potential, and promote mitochondrial function (as measured by reduced cyclophilin D and increased peroxiredoxins) has been proven capable of stimulating neurite outgrowth, preventing tau-dimerization, and protecting against Aβ-induced neurotoxicity [496,528,529].